{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:24:12Z","timestamp":1791894252080,"version":"4.3.4"},"reference-count":57,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The lysine acetyltransferase (KAT) activity of EP300 lysine acetyltransferase (p300)\/CREB-binding protein (CREBBP) has traditionally been linked to transcriptional activation. This has been attributed largely to acetylation of histone residues such as histone H3 lysine 27 acetylation (H3K27ac), a defining hallmark of active regulatory elements. Here we show that, in acute myeloid leukemia (AML), inhibition of p300\/CREBBP catalysis can paradoxically increase transcription. We combined time-resolved dynamics of nascent and total transcription with chromatin binding dynamics of p300\/CREBBP and their associated transcription factors (TFs)\/coregulators (inferred from chromatin pulldown proteomics, acetyl proteomics, and motif enrichment) to uncover mechanisms of transcriptional rewiring after p300\/CREBBP catalytic inhibition. In parallel, we dissected the functional contribution of individual p300\/CREBBP acetyl-interactome members to KAT inhibition using genome-wide CRISPR-Cas9 dropout and focused Perturb-seq screens. Together, these approaches revealed that KAT inhibition paradoxically retains p300\/CREBBP, and promotes cooperative TF assembly and increased H3K27 acetylation at a subset of regulatory elements. The effect was most pronounced at interferon regulatory factor (IRF) motif-enriched loci, including interferon-stimulated genes (ISGs), where KAT inhibition triggered p300\/CREBBP accumulation and enhanced combinatorial TF binding, enabling recruitment of the ISG activator STAT1. Consequently, ISG loci were converted into transcriptionally active states that induced cell-cycle arrest, differentiation, and apoptosis. Therapeutically, combining KAT inhibition with interferon-alpha augmented ISG expression, synergistically drove AML cell death in vitro, and significantly extended survival in both AML xenografts and murine models. These findings refine our understanding of p300\/CREBBP KAT activity, demonstrating that cooperative TF assembly can reconfigure p300\/CREBBP-containing complexes under catalytic inhibition to induce transcription, with translational implications for reprogramming interferon-driven programs through catalytic inhibition in AML and beyond.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031924","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:59:04Z","timestamp":1773853144000},"page":"84-102","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Inhibition of p300\/CREBBP catalytic activity drives context-dependent transcriptional activation in AML"],"prefix":"10.1182","volume":"148","author":[{"given":"Markus","family":"Meyerh\u00f6fer","sequence":"first","affiliation":[{"name":"1Department of Hematology and Oncology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"2German Cancer Consortium, partner site Frankfurt\/Mainz, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Zhou","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"2German Cancer Consortium, partner site Frankfurt\/Mainz, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9758-6633","authenticated-orcid":false,"given":"Aaron","family":"Gallego-Crespo","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"2German Cancer Consortium, partner site Frankfurt\/Mainz, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1334-8121","authenticated-orcid":false,"given":"Viral","family":"Shah","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"2German Cancer Consortium, partner site Frankfurt\/Mainz, Heidelberg, Germany"},{"name":"3Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1011-5919","authenticated-orcid":false,"given":"Malte","family":"Behrendt","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"2German Cancer Consortium, partner site Frankfurt\/Mainz, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Saura-Panella","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"2German Cancer Consortium, partner site Frankfurt\/Mainz, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"H\u00e4upl","sequence":"additional","affiliation":[{"name":"2German Cancer Consortium, partner site Frankfurt\/Mainz, Heidelberg, Germany"},{"name":"4Department of Medicine, Hematology and Oncology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany"},{"name":"5Frankfurt Cancer Institute, Frankfurt am Main, Germany"},{"name":"6German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5293-3293","authenticated-orcid":false,"given":"Oleksandr","family":"Todoriuk","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"2German Cancer Consortium, partner site Frankfurt\/Mainz, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6074-6961","authenticated-orcid":false,"given":"Monika","family":"Hartmann","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"2German Cancer Consortium, partner site Frankfurt\/Mainz, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Klein","sequence":"additional","affiliation":[{"name":"7Research Center for Immunotherapy, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"8Institute of Immunology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5156-2906","authenticated-orcid":false,"given":"Catherine","family":"W\u00f6lfel","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"2German Cancer Consortium, partner site Frankfurt\/Mainz, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia S.","family":"H\u00e4hnel","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"2German Cancer Consortium, partner site Frankfurt\/Mainz, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1596-3763","authenticated-orcid":false,"given":"Christian S.","family":"Michel","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"2German Cancer Consortium, partner site Frankfurt\/Mainz, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Muth","sequence":"additional","affiliation":[{"name":"7Research Center for Immunotherapy, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"8Institute of Immunology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-0507","authenticated-orcid":false,"given":"Thomas","family":"Kindler","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"2German Cancer Consortium, partner site Frankfurt\/Mainz, Heidelberg, Germany"},{"name":"7Research Center for Immunotherapy, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3232-8065","authenticated-orcid":false,"given":"Tobias","family":"Bopp","sequence":"additional","affiliation":[{"name":"2German Cancer Consortium, partner site Frankfurt\/Mainz, Heidelberg, Germany"},{"name":"7Research Center for Immunotherapy, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"8Institute of Immunology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansj\u00f6rg","family":"Schild","sequence":"additional","affiliation":[{"name":"7Research Center for Immunotherapy, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"8Institute of Immunology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8418-5783","authenticated-orcid":false,"given":"Sarah J.","family":"Horton","sequence":"additional","affiliation":[{"name":"9Department of Haematology and Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3991-5721","authenticated-orcid":false,"given":"Markus","family":"Radsak","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"2German Cancer Consortium, partner site Frankfurt\/Mainz, Heidelberg, Germany"},{"name":"7Research Center for Immunotherapy, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Theobald","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"2German Cancer Consortium, partner site Frankfurt\/Mainz, Heidelberg, Germany"},{"name":"7Research Center for Immunotherapy, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4337-8022","authenticated-orcid":false,"given":"George S.","family":"Vassiliou","sequence":"additional","affiliation":[{"name":"9Department of Haematology and Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0312-161X","authenticated-orcid":false,"given":"Brian J. P.","family":"Huntly","sequence":"additional","affiliation":[{"name":"9Department of Haematology and Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W. M.","family":"K\u00fchn","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"2German Cancer Consortium, partner site Frankfurt\/Mainz, Heidelberg, Germany"},{"name":"7Research Center for Immunotherapy, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk","family":"Butter","sequence":"additional","affiliation":[{"name":"10Institute of Molecular Biology, Mainz, Germany"},{"name":"11Institute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut, Greifswald, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Oellerich","sequence":"additional","affiliation":[{"name":"2German Cancer Consortium, partner site Frankfurt\/Mainz, Heidelberg, Germany"},{"name":"4Department of Medicine, Hematology and Oncology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany"},{"name":"5Frankfurt Cancer Institute, Frankfurt am Main, Germany"},{"name":"6German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0330-7959","authenticated-orcid":false,"given":"Daniel","family":"Sasca","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"2German Cancer Consortium, partner site Frankfurt\/Mainz, Heidelberg, Germany"},{"name":"7Research Center for Immunotherapy, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"12Institute for Quantitative and Computational Biosciences, Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2026070211222278000_bib1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"24","key":"2026070211222278000_bib2","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2026070211222278000_bib3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"2026070211222278000_bib4","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1016\/S2352-3026(24)00132-7","article-title":"Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study","volume":"11","author":"Salamero","year":"2024","journal-title":"Lancet Haematol"},{"issue":"16","key":"2026070211222278000_bib5","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"2026070211222278000_bib6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/1078-0432.CCR-22-1284","article-title":"A phase I\/II open-label study of molibresib for the treatment of relapsed\/refractory hematologic malignancies","volume":"29","author":"Dawson","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"7954","key":"2026070211222278000_bib7","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"6","key":"2026070211222278000_bib8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0092-8674(00)81063-6","article-title":"Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation","volume":"84","author":"Brownell","year":"1996","journal-title":"Cell"},{"issue":"5","key":"2026070211222278000_bib9","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0092-8674(00)82001-2","article-title":"The transcriptional coactivators p300 and CBP are histone acetyltransferases","volume":"87","author":"Ogryzko","year":"1996","journal-title":"Cell"},{"issue":"7231","key":"2026070211222278000_bib10","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/nature07730","article-title":"ChIP-seq accurately predicts tissue-specific activity of enhancers","volume":"457","author":"Visel","year":"2009","journal-title":"Nature"},{"issue":"6043","key":"2026070211222278000_bib11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1126\/science.1201662","article-title":"The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation","volume":"333","author":"Wang","year":"2011","journal-title":"Science"},{"issue":"7789","key":"2026070211222278000_bib12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41586-019-1835-6","article-title":"HBO1 is required for the maintenance of leukaemia stem cells","volume":"577","author":"MacPherson","year":"2020","journal-title":"Nature"},{"issue":"6517","key":"2026070211222278000_bib13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/374081a0","article-title":"A family of transcriptional adaptor proteins targeted by the E1A oncoprotein","volume":"374","author":"Arany","year":"1995","journal-title":"Nature"},{"issue":"13","key":"2026070211222278000_bib14","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1101\/gad.14.13.1553","article-title":"CBP\/p300 in cell growth, transformation, and development","volume":"14","author":"Goodman","year":"2000","journal-title":"Genes Dev"},{"issue":"7180","key":"2026070211222278000_bib15","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/nature06546","article-title":"The structural basis of protein acetylation by the p300\/CBP transcriptional coactivator","volume":"451","author":"Liu","year":"2008","journal-title":"Nature"},{"issue":"1","key":"2026070211222278000_bib16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cell.2018.04.033","article-title":"Time-resolved analysis reveals rapid dynamics and broad scope of the CBP\/p300 acetylome","volume":"174","author":"Weinert","year":"2018","journal-title":"Cell"},{"issue":"10","key":"2026070211222278000_bib17","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.molcel.2021.03.008","article-title":"Enhancers are activated by p300\/CBP activity-dependent PIC assembly, RNAPII recruitment, and pause release","volume":"81","author":"Narita","year":"2021","journal-title":"Mol Cell"},{"issue":"6908","key":"2026070211222278000_bib18","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nature01062","article-title":"A transcription-factor-binding surface of coactivator p300 is required for haematopoiesis","volume":"419","author":"Kasper","year":"2002","journal-title":"Nature"},{"issue":"17","key":"2026070211222278000_bib19","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1038\/emboj.2010.176","article-title":"Oncogenesis by sequestration of CBP\/p300 in transcriptionally inactive hyperacetylated chromatin domains","volume":"29","author":"Reynoird","year":"2010","journal-title":"EMBO J"},{"issue":"9","key":"2026070211222278000_bib20","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/s41594-018-0114-9","article-title":"The ZZ domain of p300 mediates specificity of the adjacent HAT domain for histone H3","volume":"25","author":"Zhang","year":"2018","journal-title":"Nat Struct Mol Biol"},{"issue":"6735","key":"2026070211222278000_bib21","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/20974","article-title":"Structure and ligand of a histone acetyltransferase bromodomain","volume":"399","author":"Dhalluin","year":"1999","journal-title":"Nature"},{"issue":"7674","key":"2026070211222278000_bib22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nature24028","article-title":"Discovery of a selective catalytic p300\/CBP inhibitor that targets lineage-specific tumours","volume":"550","author":"Lasko","year":"2017","journal-title":"Nature"},{"issue":"1","key":"2026070211222278000_bib23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1021\/acsmedchemlett.7b00395","article-title":"Discovery of spiro oxazolidinediones as selective, orally bioavailable inhibitors of p300\/CBP histone acetyltransferases","volume":"9","author":"Michaelides","year":"2018","journal-title":"ACS Med Chem Lett"},{"issue":"23","key":"2026070211222278000_bib24","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.1158\/0008-5472.CAN-15-0236","article-title":"Generation of a selective small molecule inhibitor of the CBP\/p300 bromodomain for leukemia therapy","volume":"75","author":"Picaud","year":"2015","journal-title":"Cancer Res"},{"issue":"12","key":"2026070211222278000_bib25","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.ccell.2023.11.001","article-title":"Therapeutic targeting of EP300\/CBP by bromodomain inhibition in hematologic malignancies","volume":"41","author":"Nicosia","year":"2023","journal-title":"Cancer Cell"},{"issue":"5","key":"2026070211222278000_bib26","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","article-title":"Targeting the p300\/CBP axis in lethal prostate cancer","volume":"11","author":"Welti","year":"2021","journal-title":"Cancer Discov"},{"issue":"8","key":"2026070211222278000_bib27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrg.2016.59","article-title":"The molecular hallmarks of epigenetic control","volume":"17","author":"Allis","year":"2016","journal-title":"Nat Rev Genet"},{"issue":"1","key":"2026070211222278000_bib28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41588-018-0270-1","article-title":"Subtype-specific regulatory network rewiring in acute myeloid leukemia","volume":"51","author":"Assi","year":"2019","journal-title":"Nat Genet"},{"issue":"6","key":"2026070211222278000_bib29","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.molcel.2015.04.011","article-title":"BET bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia","volume":"58","author":"Roe","year":"2015","journal-title":"Mol Cell"},{"issue":"5","key":"2026070211222278000_bib30","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cell.2016.09.018","article-title":"Ever-changing landscapes: transcriptional enhancers in development and evolution","volume":"167","author":"Long","year":"2016","journal-title":"Cell"},{"issue":"7","key":"2026070211222278000_bib31","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1182\/blood.2022019306","article-title":"Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation","volume":"145","author":"Shah","year":"2025","journal-title":"Blood"},{"issue":"11","key":"2026070211222278000_bib32","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1158\/2159-8290.CD-20-1793","article-title":"Selective requirement of MYB for oncogenic hyperactivation of a translocated enhancer in leukemia","volume":"11","author":"Smeenk","year":"2021","journal-title":"Cancer Discov"},{"issue":"18","key":"2026070211222278000_bib33","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1242\/dev.037127","article-title":"CBP-mediated acetylation of histone H3 lysine 27 antagonizes Drosophila Polycomb silencing","volume":"136","author":"Tie","year":"2009","journal-title":"Development"},{"issue":"50","key":"2026070211222278000_bib34","doi-asserted-by":"crossref","first-page":"21931","DOI":"10.1073\/pnas.1016071107","article-title":"Histone H3K27ac separates active from poised enhancers and predicts developmental state","volume":"107","author":"Creyghton","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2026070211222278000_bib35","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/s41588-022-01091-2","article-title":"Histone editing elucidates the functional roles of H3K27 methylation and acetylation in mammals","volume":"54","author":"Sankar","year":"2022","journal-title":"Nat Genet"},{"issue":"6","key":"2026070211222278000_bib36","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1021\/acsmedchemlett.0c00155","article-title":"Discovery of CPI-1612: a potent, selective, and orally bioavailable EP300\/CBP histone acetyltransferase inhibitor","volume":"11","author":"Wilson","year":"2020","journal-title":"ACS Med Chem Lett"},{"issue":"4","key":"2026070211222278000_bib37","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.chembiol.2020.12.004","article-title":"Targeted degradation of the enhancer lysine acetyltransferases CBP and p300","volume":"28","author":"Vannam","year":"2021","journal-title":"Cell Chem Biol"},{"issue":"10","key":"2026070211222278000_bib38","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s41588-021-00925-9","article-title":"Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression","volume":"53","author":"Yun","year":"2021","journal-title":"Nat Genet"},{"issue":"9","key":"2026070211222278000_bib39","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/leu.2013.77","article-title":"A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice","volume":"27","author":"Mupo","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"2026070211222278000_bib40","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","article-title":"Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b","volume":"36","author":"Kiladjian","year":"2022","journal-title":"Leukemia"},{"issue":"19","key":"2026070211222278000_bib41","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A randomized phase 3 trial of interferon-alpha vs hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2026070211222278000_bib42","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"issue":"8","key":"2026070211222278000_bib43","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2026070211222278000_bib44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood.2024026513","article-title":"How I manage chronic myeloid leukemia during pregnancy","volume":"147","author":"Abruzzese","year":"2025","journal-title":"Blood"},{"issue":"6","key":"2026070211222278000_bib45","first-page":"577","article-title":"Alpha interferon in the treatment of chronic myelomonocytic leukemia","volume":"74","author":"Catalano","year":"1989","journal-title":"Haematologica"},{"issue":"3","key":"2026070211222278000_bib46","first-page":"220","article-title":"Phase II trial of recombinant human interferon alpha in myelodysplastic syndromes","volume":"6","author":"Nand","year":"1992","journal-title":"Leukemia"},{"issue":"5","key":"2026070211222278000_bib47","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/leu.2010.324","article-title":"Interferon-alpha in acute myeloid leukemia: an old drug revisited","volume":"25","author":"Anguille","year":"2011","journal-title":"Leukemia"},{"issue":"19","key":"2026070211222278000_bib48","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1016\/j.molcel.2022.09.005","article-title":"p300\/CBP sustains Polycomb silencing by non-enzymatic functions","volume":"82","author":"Hunt","year":"2022","journal-title":"Mol Cell"},{"issue":"2","key":"2026070211222278000_bib49","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.molcel.2023.12.004","article-title":"p300 is an obligate integrator of combinatorial transcription factor inputs","volume":"84","author":"Ferrie","year":"2024","journal-title":"Mol Cell"},{"issue":"6486","key":"2026070211222278000_bib50","doi-asserted-by":"crossref","first-page":"eaax6367","DOI":"10.1126\/science.aax6367","article-title":"Structural basis for allosteric PARP-1 retention on DNA breaks","volume":"368","author":"Zandarashvili","year":"2020","journal-title":"Science"},{"issue":"6598","key":"2026070211222278000_bib51","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/383344a0","article-title":"Cooperation of Stat2 and p300\/CBP in signalling induced by interferon-alpha","volume":"383","author":"Bhattacharya","year":"1996","journal-title":"Nature"},{"issue":"36","key":"2026070211222278000_bib52","doi-asserted-by":"crossref","first-page":"25343","DOI":"10.1074\/jbc.274.36.25343","article-title":"Stat protein transactivation domains recruit p300\/CBP through widely divergent sequences","volume":"274","author":"Paulson","year":"1999","journal-title":"J Biol Chem"},{"issue":"7","key":"2026070211222278000_bib53","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/emboj.2009.30","article-title":"Structural basis for recruitment of CBP\/p300 coactivators by STAT1 and STAT2 transactivation domains","volume":"28","author":"Wojciak","year":"2009","journal-title":"EMBO J"},{"issue":"7","key":"2026070211222278000_bib54","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1158\/2159-8290.CD-21-0956","article-title":"Unleashing cell-intrinsic inflammation as a strategy to kill AML blasts","volume":"12","author":"Ellegast","year":"2022","journal-title":"Cancer Discov"},{"issue":"6682","key":"2026070211222278000_bib55","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/30538","article-title":"Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation","volume":"393","author":"Kawasaki","year":"1998","journal-title":"Nature"},{"issue":"16","key":"2026070211222278000_bib56","doi-asserted-by":"crossref","first-page":"5396","DOI":"10.1093\/nar\/gkq184","article-title":"Genome-wide assessment of differential roles for p300 and CBP in transcription regulation","volume":"38","author":"Ramos","year":"2010","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2026070211222278000_bib57","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12860-020-00296-9","article-title":"Differential contribution of p300 and CBP to regulatory element acetylation in mESCs","volume":"21","author":"Martire","year":"2020","journal-title":"BMC Mol Cell Biol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/1\/84\/2531403\/blood_bld-2025-031924-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/1\/84\/2531403\/blood_bld-2025-031924-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:32:43Z","timestamp":1783006363000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/1\/84\/567280\/Inhibition-of-p300-CREBBP-catalytic-activity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031924","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,2]]},"published":{"date-parts":[[2026,7,2]]}}}